A clinical study to evaluate the safety, tolerability and efficacy of combining surufatinib and fruquintinib with tislelizumab, for the treatment of various solid tumor cancers
Latest Information Update: 21 Sep 2022
At a glance
- Drugs Fruquintinib (Primary) ; Surufatinib (Primary) ; Tislelizumab (Primary)
- Indications Cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 26 May 2020 According to an Chi-Med, BeiGene media release, initial focus of the agreement is on multi-cohort trials in the U.S., Europe, China and Australia.
- 26 May 2020 According to an Chi-Med, BeiGene media release, the companies have entered into a clinical collaboration agreement to evaluate the safety, tolerability and efficacy of combining two of Chi-Med's drug candidates, surufatinib and fruquintinib, with BeiGene's anti-PD-1 antibody tislelizumab, for the treatment of various solid tumor cancers, in the U.S., Europe, China and Australia.
- 26 May 2020 New trial record